Stock CABA CABALETTA BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Cabaletta Bio, Inc.

Equities

CABA

US12674W1099

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
10.48 USD -4.81% Intraday chart for Cabaletta Bio, Inc. -21.32% -53.83%
Mar. 22 HC Wainwright Adjusts Cabaletta Bio's Price Target to $30 From $25, Maintains Buy Rating MT
Mar. 21 Cabaletta Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
HC Wainwright Adjusts Cabaletta Bio's Price Target to $30 From $25, Maintains Buy Rating
MT
Cabaletta Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
GL
Cabaletta Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Cabaletta Bio Gets Orphan Drug Designation From FDA For Systemic Sclerosis Treatment
MT
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
GL
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
AQ
North American Morning Briefing : Markets on Hold -2-
DJ
North American Morning Briefing : Stock Futures -2-
DJ
Cabaletta Bio to Participate in Upcoming Investor Conferences in March
GL
Jefferies Initiates Cabaletta Bio with Buy Rating, $36 Price Target
MT
Cabaletta Bio Secures Orphan Drug Designation for Myositis Treatment
MT
Cabaletta Bio Gets Orphan Drug Designation for Potential Autoimmune Disease Treatment
DJ
Cabaletta, Inc. Announces FDA Grants Orphan Drug Designation to CABA-201
CI
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis
GL
Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
GL
Transcript : Cabaletta Bio, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 05:15 PM
Cabaletta Bio Gets Additional FDA Fast Track Labels For CABA-201
MT
Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis
GL
Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CABA Stock
  4. News Cabaletta Bio, Inc.